HPV16 E7 (86-93) (TFA)

This HLA-A2.1-restricted peptide, derived from the HPV16 E7 oncoprotein, demonstrates immunogenicity in cervical cancer models. It is a key research tool for studying antigen-specific T-cell responses, vaccine development, and immunotherapy mechanisms in both in vitro and in vivo experimental settings.